The SA Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC) was established in 1998 under a NHMRC Centres of Clinical Excellence Grant. It is an ongoing collaborative venture of the University of Adelaide, Flinders University of South Australia, The Queen Elizabeth (TQEH), the Royal Adelaide (RAH), and the Repatriation General Hospital (RGH).

SA-PCCOC is a disease-specific registry and longitudinal observational study comprising men diagnosed with pathologically proven prostate cancer (CaP) in South Australia. The database follows men with prostate cancer treated at the three major metropolitan hospitals: the Royal Adelaide Hospital, The Queen Elizabeth Hospital, and Flinders Medical Centre/Repatriation General Hospital and a number of private practices are also included. Patients are followed to death or withdrawal.

Please visit our website for more information.

What we measure
Outomes
Who can apply to use our data
Prostate Health Consumer Website
Committees
Presentations & publications

 

What we measure

We collect PSA at diagnosis, diagnostic pathology including Gleason primary and secondary clinical stage, treatment type and attributes and prostate pathology for radical prostatectomy patients. Patients complete an Expanded Prostate Cancer Index Composite questionnaire at baseline, 3, 6, 12 months, 2 and 5 years.

Back to top


Outcomes

Outcomes measured include biochemical recurrence, prostate-specific death and death from any cause, pathology, treatment outcomes and complications and patient-reported symptoms.

 Back to top


Who can apply to use our data

We welcome collaborations with individual clinicians, scientists and organisations with a focus on prostate cancer. All analyses undergo ethical consideration. Results are made available publicly through presentation and publication.

 Back to top


Prostate Health Consumer Website

SAPCCOC also maintains the Prostate Health consumer website for:

  • Men and their families diagnosed with Prostate Cancer.
  • Clinicians and other health professionals who need information on Prostate Cancer education issues.

 Back to top


Committees

The database is governed by a steering committee and managed by three staff members based at the Repatriation general Hospital.

Membership

Membership is drawn from clinicians contributing data, with each hospital represented, together with a representative from major SA cancer data initiatives which form the SA Cancer data strategy, a consumer member and other relevant persons:

  • One data contributor from each hospital
  • Two reps from management committee
  • CNC Urology, Repatriation General hospital
  • A consumer and Prostate Cancer Foundation of Australia representative.
  • A representative from the Cancer Council South Australia.
  • Chairman & Principal Investigator: Kim Moretti
  • Deputy Chairman: Kym Horsell
  • Dr Michael O’Callaghan
  • Research Advisor: Carole Pinnock
  • Martin Borg
  • Kym Pese
  • Peter Sutherland
  • Kerri Beckmann
  • Michael Chong
  • Darren Foreman
  • Tina Kopsaftis
  • Scott Walsh
  • David Roder
  • Jimmy Lam
  • Jason Lee
  • Leigh Pretty (Urology CNC)
  • Jeff Roberts

Role of committee

The steering committee gives strategic direction and provides governance for the database. Day to day decisions are taken by the management committee (comprises database team and researchers). It will decide:

  • Ownership of and access to the data
  • Reporting of the data
  • How to facilitate research
  • Policy on authorship
  • Data collected – ideally consistent with other prostate cancer clinical registries such as those in Victoria and the Accord dataset.

Note: The database custodianship is with RGH as the corporate entity managing the funding. Auditing is done by an external auditor of the RGH trust funds

Management Committee

The management committee comprises the Data Manager, Clinical Data Coordinator, Data Analyst and is responsible for the day-to-day running of the database and quality audits.

  • Dr Michael O’Callaghan
  • Tina Kopsaftis
  • Scott Walsh

Research Committee

  • Chairman: Martin Borg
  • Dr Michael O’Callaghan
  • Grant Buchanan
  • Kim Moretti
  • Kerri Beckmann
  • Michael Chong
  • Darren Foreman
  • Kym Horsell
  • Carole Pinnock
  • Tina Kopsaftis
  • Scott Walsh
  • Jimmy Lam
  • Daniel Spernat
  • Ganessan Kichenadasse
  • Jason Lee

Back to top


Presentations & Publications

Publications

Andrew P. Trotta, Eleanor F. Need, Luke A. Selth, Samarth Choprac, Carole B. Pinnock, Damien A. Leach, Gerhard A Coetzee, Lisa M. Butler, Wayne D. Tilley and Grant Buchanan, Knockdown of the co-chaperone SGTA results in the suppression of androgen and PI3K/AKT signaling and inhibition of prostate cancer cell proliferation, International of Journal of Cancer2013 Jun 6. doi: 10.1002/ijc.28310, Supplementary figures

L Osei-Tutu, S Plagakis, J Lee, C Pinnock, K L Moretti. Upgrading of standard and Transperineal Transrectal Ultrasound Guided Prostate Biopsies on Subsequent Radical Prostatectomy: A Population Based Study. The Internet Journal of Urology, 2013 Volume 11 No.1 http://ispub.com/iju/11/1/1504

Stephen Kinsey-Trotman, Zumin Shi, Carole Pinnock, Martin Borg, Kim Moretti, Scott Walsh, Tina Kopsaftis. Prostate-Specific Antigen (PSA) rate of decline post external beam radiotherapy may predict prostate cancer death, Published: Radiotherapy and Oncology Journal  2013 May;107(2):129-33 Jason Lee The rate of upgrading of TRUS biopsy results in intermediate risk prostate cancer, SADVH Research Paper Day August 2012 RGH. Abstract published in the Journal of Military and Veteran Health 2012, Nov; 20 (4): 71-72

Tamblyn, DJ, Samarth Chopra, Changhong Yu, Michael W. Kattan, Carole Pinnock, Tina Kopsaftis Comparative analysis of three risk assessment tools in Australian prostate cancer patients. BJUI (108 supp 2), November 2011, p 51-57. Tamblyn risk Assessment Tools

Beckmann, K., et al., Clinical and socio-demographic profile of an Australian multi-institutional prostate cancer cohort, Asia Pacific Journal Clin Oncol, 2009. 5: p. 247-256. Pdf document

Stapleton, A.M., et al., Abnormal PSA tests--delays in referral. Australian Family Physician, 2008. 37(1-2): p. 84-8. Delayed referral pdf

Stapleton, A. and C.B. Pinnock, Nomograms for prostate cancer - is their use evidence-based? Nature Clinical Practice Urology, 2005. 2(10): p. 462-463. Nomograms Abstract

Ben-Tovim, D., Dougherty, M., Stapleton, A., and Pinnock, C. Coping with prostate cancer: A quantitative analysis using a new instrument, the CCCI. Urology, 2002; 59 (3):383-8
Coping with Prostate Cancer pdf

Submitted for Publication

Damien A. Leach, Eleanor F. Need, Samarth Chopra, David J. Tamblyn Tina Kopsaftis Georgina M. England Carole B. Pinnock Gail P. Risbridger, Lee Peng,Renea A. Taylor, Grant Buchanan Loss of stromal androgen receptor depletes the protective mircroenvironment and leads to poor outcome in prostate cancer Submitted to Journal of the National Cancer Institute (JNCI) March 2013

Abstract Presentations

Analysis of Quality of Life survey response rates from the South Australian Prostate Cancer Clinical Outcomes Collaborative. L.Osei-Tutu. Abstract presented to 66th USANZ National Meeting in Melbourne in 2013 QOL Abstract

Radical Prostatectomy: do positive surgical margins at the apex matter? P. Penkoff, Carole Pinnock, Kym Horsell, Kim Moretti, Scott Walsh, Tina Kopsaftis, and the SA-Prostate Cancer Clinical Outcomes Collaborative. Abstract presented at the local USANZ meeting Port Lincoln, October 2012. Awarded ‘St Paul Ball’ for best presentation; submitted to 66th USANZ National Meeting Melbourne in 2013

Analysis of transperineal biopsy and subsequent radical prostatectomy, utilising the SA-PCCOC database: L.Osei-Tutu, S. Walsh, T. Kopsaftis, J. Lee. Abstract presented at the local USANZ meeting Port Lincoln, October 2012; submitted to 66th USANZ National Meeting in Melbourne in 2013 Transperineal Biopsy Upgrade Abstract

An update of the South Australian Prostate Cancer Clinical Outcomes Collaborative Jason Lee, on behalf of SA Prostate Cancer Outcomes Collaborative (SA-PCCOC), Steering Committee and Management Team. Abstract presented at the local USANZ meeting Port Lincoln October 2012

SA Prostate Cancer Clinical Outcomes Collaborative (SA –PCCOC) Dr Kim Moretti , SA Prostate Cancer Research Meeting: ‘Current Programs and Developing Linkages and Research Capacity’, National Wine Centre, Adelaide, 5th October 2012

The rate of upgrading of TRUS biopsy results in intermediate risk prostate cancer
Jason Lee, Sophie Plagakis. Abstract presented at the SA section USANZ meeting October 2011 and USANZ National meeting in Darwin March 2012

Poorly differentiated low PSA prostate cancer: Evaluation of survival and treatment outcomes Alexander Jay, Carole Pinnock, Tina Kopsaftis, David Tamblyn and Kim Moretti. Abstract presented at the SA section USANZ meeting October 2011 and USANZ National meeting in Darwin March 2012

Comparison of TRUS Biopsy and Subsequent Radical Prostatectomy Histology to Assess Rate of Upgrading in Gleason 3+4 Prostate Cancer Lee J, Plagakis S. Abstract presented at the SA section USANZ meeting October 2011 and USANZ National meeting in Darwin March 2012

 Back to top